NuLignan™
7-hydroxymatairesinol extract
Therapeutic Actions
1. Promotes hormonal health by promoting the body's own production of
enterolactone, which has been found to be protect against developing
tumors and cardiovascular disease
2. Enterolactone reduces circulating estrogen, and blocks aromatase, binds to
estrogen receptors and blocks estrogen activity in specific selected tissues,
inhibits cancer cell growth and signaling. When estrogen levels decline,
enterolactone levels may mimic the effects of estrogen, when estrogen
levels are high, enterolactone occupies and blocks estrogen receptors
3. Reduces hot flashes; may support bone health
4. Antioxidant, anti-inflammatory
Administration
Internal:
For hot flashes and for acute conditions use 2 tablets day.
Maintenance dosage 1 tablet per day
90 tablets, 25mg, 30 day supply
Ingredient
A patented extract of
7-hydroxymatairesinol extracted from
Norway Spruce Trees (Picea abies)
Formula Rationale
Lignans are phyto-nutrients found in unrefined grain products, seeds, fruits and
vegetables. Friendly intestinal bacteria converts plant lignans into human lignans such
as enterolactone. When there are low estrogen levels in the body these weak lignan
estrogens make up for some of the insufficiency. When estrogen from endogenous or
exogenous sources is abundant, enterolactone reduces the activity of estrogen by
occupying estrogen binding sites. As a result, plant lignans are thought to influence the
development of breast, prostate, and colon cancers that depend on hormones to start
and progress. Lignans also support cardiovascular health and help to moderate other
estrogen dependant conditions such as menopausal symptoms and osteoporosis.
Case control studies in Finland found an inverse association between serum
enterolactone and the risk of breast cancer both among pre-menopausal and postmenopausal
women. These findings have been duplicated in case control studies in
Australia and the UK. In a study conducted by the Roswell Park Cancer Institute, U.S.A,
of 1,122 women with primary breast cancer, and 2,036 control subjects, that those with
the highest dietary intake of lignans had a reduced breast cancer risk.
Research has shown that enterolactone acts weakly on the physiological estrogen
balance and offers a natural method for managing menopausal symptoms. In an eight
week study, the equivalent to two tablets of NuLignan™ was found to increase
enterolactone levels and significantly reduce hot flashes at week four, with further
reductions at week eight. Additional studies suggest that lignans improve menopausal
symptoms, and maintain cognitive function in postmenopausal women. Recent studies
suggest a link between lignan consumption and bone reabsorption, and improved lipid
profiles. Lignans are also thought to contribute to prostate health by inhibiting cancer
cell growth and signaling.
NuLignan is a new generation, highly bioavailable lignan formula. It is the first direct
enterolactone precursor supplement, standardized to 90 percent pure lignans as 7-
hydroxymatairesinol. In addition, it is a strong antioxidant, and may help to modulate
inflammatory reactions. Pharmacokinetic studies show that NuLignan is rapidly
absorbed, elevates enterolactone concentration, and has an excellent safety profile.
